Yasuhiro Funahashi

E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition

Junji Matsui, Yuji Yamamoto, Yasuhiro Funahashi et al. · International Journal of Cancer · 2007 · 547 citations

Medicine, Oncology, Pharmacology +17

Multi-Kinase Inhibitor E7080 Suppresses Lymph Node and Lung Metastases of Human Mammary Breast Tumor MDA-MB-231 via Inhibition of Vascular Endothelial Growth Factor-Receptor (VEGF-R) 2 and VEGF-R3 Kinase

Junji Matsui, Yasuhiro Funahashi, Toshimitsu Uenaka et al. · Clinical Cancer Research · 2008 · 528 citations · Full text

Medicine, Oncology, Pharmacology +17

Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage

Yuji Yamamoto, Junji Matsui, Tomohiro Matsushima et al. · Vascular Cell · 2014 · 500 citations · Full text

Medicine, Oncology, Pharmacology +16

Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models

Osamu Tohyama, Junji Matsui, Kotaro Kodama et al. · Journal of Thyroid Research · 2014 · 480 citations · Full text

Medicine, Oncology, Pharmacology +17

Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway

Yu Kato, Kimiyo Tabata, Takayuki Kimura et al. · PLoS ONE · 2019 · 463 citations · Full text

Life Sciences, Immunology, Oncology +17